Copyright © 2021. Inderes Oyj. All rights reserved.

Genovis Q1: Undramatic - Redeye

Muut analyysit 29.04.2021 13:52 Genovis AB

Redeye’s first impression of Genovis Q1’21 is that it is a pretty solid report in the core business, given that customer activity remains regionally sluggish due to the pandemic.

Lähde: Finwire News

Genovis AB provides enzymes and technologies for analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce and market tools for developing new drugs and diagnostics. The Genovis product line comprises of GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company serves mainly the medical device and pharmaceutical industries.